-
1
-
-
0032511583
-
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
-
UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853
-
(1998)
Lancet
, vol.352
, pp. 837-853
-
-
-
2
-
-
82755165018
-
Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials
-
PID: 22115901
-
Hemmingsen B, Schroll JB, Wetterslev J et al (2011) Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 343:d6898
-
(2011)
BMJ
, vol.343
, pp. d6898
-
-
Hemmingsen, B.1
Schroll, J.B.2
Wetterslev, J.3
-
3
-
-
79960959816
-
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
-
PID: 21791495
-
Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi et al (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169
-
(2011)
BMJ
, vol.343
, pp. d4169
-
-
Boussageon, R.1
Bejan-Angoulvant, T.2
Saadatian-Elahi3
-
4
-
-
85016474227
-
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials
-
PID: 28365411
-
Zoungas S, Arima H, Gerstein HC et al (2017) Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 5:431–437
-
(2017)
Lancet Diabetes Endocrinol
, vol.5
, pp. 431-437
-
-
Zoungas, S.1
Arima, H.2
Gerstein, H.C.3
-
5
-
-
84954100087
-
Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies
-
PID: 26769243
-
Pladevall M, Riera-Guardia N, Margulis AV, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S (2016) Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies. BMC Cardiovasc Disord 16:14
-
(2016)
BMC Cardiovasc Disord
, vol.16
, pp. 14
-
-
Pladevall, M.1
Riera-Guardia, N.2
Margulis, A.V.3
Varas-Lorenzo, C.4
Calingaert, B.5
Perez-Gutthann, S.6
-
6
-
-
49649098865
-
Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies
-
PID: 18458139
-
Rao AD, Kuhadiya N, Reynolds K, Fonseca VA (2008) Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care 31:1672–1678
-
(2008)
Diabetes Care
, vol.31
, pp. 1672-1678
-
-
Rao, A.D.1
Kuhadiya, N.2
Reynolds, K.3
Fonseca, V.A.4
-
7
-
-
34250212715
-
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
COI: 1:CAS:528:DC%2BD2sXms1SisrY%3D, PID: 17517853
-
Nissen S, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471
-
(2007)
N Engl J Med
, vol.356
, pp. 2457-2471
-
-
Nissen, S.1
Wolski, K.2
-
8
-
-
26244453309
-
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
-
COI: 1:CAS:528:DC%2BD2MXhtVOlu7fO, PID: 16214598
-
Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279–1289
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
-
9
-
-
84937053742
-
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
-
COI: 1:CAS:528:DC%2BC2MXhtlKrtbnN, PID: 26052984
-
Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242
-
(2015)
N Engl J Med
, vol.373
, pp. 232-242
-
-
Green, J.B.1
Bethel, M.A.2
Armstrong, P.W.3
-
10
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
COI: 1:CAS:528:DC%2BC28XhvF2ks77O, PID: 27295427
-
Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322
-
(2016)
N Engl J Med
, vol.375
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
-
11
-
-
0015401059
-
A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP)
-
COI: 1:STN:280:DyaE383ms1Gnsw%3D%3D, PID: 5055722
-
Seltzer HS (1972) A summary of criticisms of the findings and conclusions of the University Group Diabetes Program (UGDP). Diabetes 21:976–979
-
(1972)
Diabetes
, vol.21
, pp. 976-979
-
-
Seltzer, H.S.1
-
12
-
-
0032511566
-
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
-
UKPDS Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865
-
(1998)
Lancet
, vol.352
, pp. 854-865
-
-
-
13
-
-
85026812421
-
Metformin: historical overview
-
Bailey CJ (2017) Metformin: historical overview. Diabetologia DOI: 10.1007/s00125-017-4318-z
-
(2017)
Diabetologia
-
-
Bailey, C.J.1
-
14
-
-
84860167144
-
Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials
-
PID: 22509138
-
Boussageon R, Supper I, Bejan-Angoulvant T et al (2012) Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 9:e1001204
-
(2012)
PLoS Med
, vol.9
-
-
Boussageon, R.1
Supper, I.2
Bejan-Angoulvant, T.3
-
15
-
-
78851470539
-
Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials
-
COI: 1:CAS:528:DC%2BC3MXjtFSgtr4%3D, PID: 21205121
-
Lamanna C, Monami M, Marchionni N, Mannucci E (2011) Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 13:221–228
-
(2011)
Diabetes Obes Metab
, vol.13
, pp. 221-228
-
-
Lamanna, C.1
Monami, M.2
Marchionni, N.3
Mannucci, E.4
-
16
-
-
84901768284
-
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
-
COI: 1:CAS:528:DC%2BC2cXpslCrsb8%3D, PID: 24910232
-
Holman RR, Sourij H, Califf RM (2014) Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet 383:2008–2017
-
(2014)
Lancet
, vol.383
, pp. 2008-2017
-
-
Holman, R.R.1
Sourij, H.2
Califf, R.M.3
-
17
-
-
69449100622
-
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
-
PID: 19622551
-
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
-
(2009)
BMJ
, vol.339
, pp. b2535
-
-
Moher, D.1
Liberati, A.2
Tetzlaff, J.3
Altman, D.G.4
-
18
-
-
32944456100
-
-
Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (2005) Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev, Issue 3, Art. no.:CD002966 (withdrawn)
-
(2005)
Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev, Issue 3, Art. no.:CD002966 (withdrawn)
-
-
Saenz, A.1
Fernandez-Esteban, I.2
Mataix, A.3
Ausejo, M.4
Roque, M.5
Moher, D.6
-
19
-
-
0036895990
-
Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes
-
PID: 12453903
-
Hällsten K, Virtanen KA, Lonnqvist F et al (2002) Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479–3485
-
(2002)
Diabetes
, vol.51
, pp. 3479-3485
-
-
Hällsten, K.1
Virtanen, K.A.2
Lonnqvist, F.3
-
20
-
-
0035663674
-
Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients
-
COI: 1:CAS:528:DC%2BD38XnvVSisg%3D%3D, PID: 11903415
-
Hermann LS, Kalen J, Katzman P et al (2001) Long-term glycaemic improvement after addition of metformin to insulin in insulin-treated obese type 2 diabetes patients. Diabetes Obes Metab 3:428–434
-
(2001)
Diabetes Obes Metab
, vol.3
, pp. 428-434
-
-
Hermann, L.S.1
Kalen, J.2
Katzman, P.3
-
21
-
-
53749096863
-
10-year follow-up of intensive glucose control in type 2 diabetes
-
COI: 1:CAS:528:DC%2BD1cXht1Wgt7nK, PID: 18784090
-
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589
-
(2008)
N Engl J Med
, vol.359
, pp. 1577-1589
-
-
Holman, R.R.1
Paul, S.K.2
Bethel, M.A.3
Matthews, D.R.4
Neil, H.A.5
-
22
-
-
63849328978
-
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus
-
COI: 1:CAS:528:DC%2BD1MXksVOntrY%3D, PID: 19307526
-
Kooy A, de Jager J, Lehert P et al (2009) Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 169:616–625
-
(2009)
Arch Intern Med
, vol.169
, pp. 616-625
-
-
Kooy, A.1
de Jager, J.2
Lehert, P.3
-
23
-
-
79951694164
-
Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study
-
PID: 20929990
-
Gram J, Henriksen JE, Grodum E et al (2011) Pharmacological treatment of the pathogenetic defects in type 2 diabetes: the randomized multicenter South Danish Diabetes Study. Diabetes Care 34:27–33
-
(2011)
Diabetes Care
, vol.34
, pp. 27-33
-
-
Gram, J.1
Henriksen, J.E.2
Grodum, E.3
-
24
-
-
0035374524
-
The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes
-
COI: 1:CAS:528:DC%2BD3MXks1agurw%3D, PID: 11375358
-
Chiasson JL, Naditch L (2001) The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 24:989–994
-
(2001)
Diabetes Care
, vol.24
, pp. 989-994
-
-
Chiasson, J.L.1
Naditch, L.2
-
25
-
-
0029099086
-
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus
-
COI: 1:CAS:528:DyaK2MXpsVanurY%3D, PID: 7623902
-
DeFronzo RA, Goodman AM, The Multicenter Metformin Study Group (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:541–549
-
(1995)
N Engl J Med
, vol.333
, pp. 541-549
-
-
DeFronzo, R.A.1
Goodman, A.M.2
-
26
-
-
0033754777
-
Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes
-
COI: 1:CAS:528:DC%2BD3cXot1ahs7s%3D, PID: 11092289
-
Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S (2000) Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 23:1660–1665
-
(2000)
Diabetes Care
, vol.23
, pp. 1660-1665
-
-
Horton, E.S.1
Clinkingbeard, C.2
Gatlin, M.3
Foley, J.4
Mallows, S.5
Shen, S.6
-
27
-
-
0036791054
-
Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications
-
COI: 1:CAS:528:DC%2BD38XnvVKmu74%3D, PID: 12384131
-
Rachmani R, Slavachevski I, Levi Z, Zadok B, Kedar Y, Ravid M (2002) Metformin in patients with type 2 diabetes mellitus: reconsideration of traditional contraindications. Eur J Intern Med 13:428–433
-
(2002)
Eur J Intern Med
, vol.13
, pp. 428-433
-
-
Rachmani, R.1
Slavachevski, I.2
Levi, Z.3
Zadok, B.4
Kedar, Y.5
Ravid, M.6
-
28
-
-
84959478814
-
Metformin as firstline treatment for type 2 diabetes: are we sure?
-
PID: 26747716
-
Boussageon RF, Gueyffier F, Cornu C (2016) Metformin as firstline treatment for type 2 diabetes: are we sure? BMJ 352:h6748
-
(2016)
BMJ
, vol.352
, pp. h6748
-
-
Boussageon, R.F.1
Gueyffier, F.2
Cornu, C.3
-
29
-
-
54949090768
-
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review
-
Selvin E, Bolen S, Yeh HC et al (2008) Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168:2070–2080
-
(2008)
Arch Intern Med
, vol.168
, pp. 2070-2080
-
-
Selvin, E.1
Bolen, S.2
Yeh, H.C.3
-
30
-
-
14644390253
-
Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study
-
COI: 1:CAS:528:DC%2BD2MXivVaisrw%3D, PID: 15735184
-
Cryer DR, Nicholas SP, Henry DH, Mills DJ, Stadel BV (2005) Comparative outcomes study of metformin intervention versus conventional approach the COSMIC Approach Study. Diabetes Care 28:539–543
-
(2005)
Diabetes Care
, vol.28
, pp. 539-543
-
-
Cryer, D.R.1
Nicholas, S.P.2
Henry, D.H.3
Mills, D.J.4
Stadel, B.V.5
-
31
-
-
84920025605
-
Metformin in patients with type 2 diabetes and kidney disease: a systematic review
-
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312:2668–2675
-
(2014)
JAMA
, vol.312
, pp. 2668-2675
-
-
Inzucchi, S.E.1
Lipska, K.J.2
Mayo, H.3
Bailey, C.J.4
McGuire, D.K.5
-
32
-
-
84907296915
-
Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders
-
Gandini S, Puntoni M, Heckman-Stoddard BM et al (2014) Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res 79:867–885
-
(2014)
Cancer Prev Res
, vol.79
, pp. 867-885
-
-
Gandini, S.1
Puntoni, M.2
Heckman-Stoddard, B.M.3
-
33
-
-
84866138849
-
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials
-
COI: 1:CAS:528:DC%2BC38XhtlWlsrjP, PID: 22875195
-
Stevens RJ, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D (2012) Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 55:2593–2603
-
(2012)
Diabetologia
, vol.55
, pp. 2593-2603
-
-
Stevens, R.J.1
Fernandez-Esteban, I.2
Mataix, A.3
Ausejo, M.4
Roque, M.5
Moher, D.6
-
34
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
COI: 1:CAS:528:DC%2BC28XntVSkurs%3D, PID: 26378978
-
Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
35
-
-
85014781627
-
Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?
-
COI: 1:CAS:528:DC%2BC2sXktFyju7c%3D, PID: 28283684
-
Florez JC (2017) Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool? Diabetologia 60:800–807
-
(2017)
Diabetologia
, vol.60
, pp. 800-807
-
-
Florez, J.C.1
-
36
-
-
0037034257
-
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
-
COI: 1:CAS:528:DC%2BD38XhtVWqurc%3D, PID: 11832527
-
Knowler WC, Barrett-Connor E, Fowler SE et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
-
(2002)
N Engl J Med
, vol.346
, pp. 393-403
-
-
Knowler, W.C.1
Barrett-Connor, E.2
Fowler, S.E.3
-
37
-
-
31844452061
-
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1)
-
Ramachandran A, Snehalatha C, Mary S et al (2006) The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289–297
-
(2006)
Diabetologia
, vol.49
, pp. 289-297
-
-
Ramachandran, A.1
Snehalatha, C.2
Mary, S.3
-
38
-
-
85026778634
-
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study
-
Aroda VR, Knowler WC, Crandal JP et al (2017) Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia DOI: 10.1007/s00125-017-4361-9
-
(2017)
Diabetologia
-
-
Aroda, V.R.1
Knowler, W.C.2
Crandal, J.P.3
-
39
-
-
4644336398
-
Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk
-
COI: 1:CAS:528:DC%2BD2cXos1Cjtrg%3D, PID: 15381514
-
Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N (2004) Association of hemoglobin A1c with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413–420
-
(2004)
Ann Intern Med
, vol.141
, pp. 413-420
-
-
Khaw, K.T.1
Wareham, N.2
Bingham, S.3
Luben, R.4
Welch, A.5
Day, N.6
-
40
-
-
84859977229
-
Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses
-
PID: 22517929
-
Hemmingsen B, Christensen LL, Wetterslev J (2012) Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 344:e1771
-
(2012)
BMJ
, vol.344
-
-
Hemmingsen, B.1
Christensen, L.L.2
Wetterslev, J.3
|